Determination of pediatric reference limits for 10 commonly measured autoantibodies
Author:
Sepiashvili Lusia123, Bohn Mary Kathryn12, Hall Alexandra1, Henderson Tina1, Chen Jack1, Dunst Roseline1, Adeli Khosrow123
Affiliation:
1. Department of Paediatric Laboratory Medicine , The Hospital for Sick Children , Toronto , ON , Canada 2. Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , ON , Canada 3. Molecular Medicine , SickKids Research Institute , Toronto , ON , Canada
Abstract
Abstract
Objectives
The objective of this study was to establish pediatric reference limits for autoimmune disease markers in the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) cohort of healthy children and adolescents to support their interpretation and clinical decision making. The CALIPER is a national study of healthy children aiming to close gaps in pediatric laboratory medicine by establishing a robust database of pediatric reference intervals for pediatric disease biomarkers (caliperdatabase.org).
Methods
Healthy children and adolescents (n=123, aged 1–19) were recruited to CALIPER with informed consent. Serum autoantibody testing conducted on the BIO-FLASH analyzer (Werfen, Barcelona, Spain) included anti-dsDNA IgG, anti-Sm IgG, anti-RNP IgG, anti-SSB/La IgG, anti-Ro60 IgG, anti-Ro52 IgG, anti-cardiolipin IgG, anti-MPO IgG, anti-PR3 IgG, and anti-tTG IgA. Pediatric reference limits representing 95th, 97.5th, and 99th percentiles were calculated using the non-parametric rank method according to Clinical Laboratory Standards Institute C28-A3 guidelines.
Results
The proportion of samples with results above the lower limit of the analytical measuring range were: anti-cardiolipin IgG 90%, anti-dsDNA 22%, anti-Sm 13%, anti-RNP 0.8%, anti-SSB/La 0%, anti-Ro60 0%, anti-Ro52 0%, anti-MPO 25%, anti-PR3 9%, and anti-tTG IgA 28%. Pediatric reference limits and associated 90% confidence intervals were established for all 10 markers. All autoantibodies could be described by one age range except for anti-cardiolipin IgG and anti-MPO. A sex-specific difference was identified for anti-tTG IgA.
Conclusions
Robust pediatric reference limits for 10 commonly clinically utilized autoimmune markers established herein will allow for improved laboratory assessment and clinical decision making in pediatric patients using the BIO-FLASH assay platform worldwide.
Funder
Canadian Institutes for Health Research Foundation Grant
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference27 articles.
1. Aggarwal, A. Role of autoantibody testing. Best Pract Res Clin Rheumatol 2014;28:907–20. https://doi.org/10.1016/j.berh.2015.04.010. 2. Olsen, NJ, Choi, MY, Fritzler, MJ. Emerging technologies in autoantibody testing for rheumatic diseases. Arthritis Res Ther 2017;19:1–10. https://doi.org/10.1186/s13075-017-1380-3. 3. Cinquanta, L, Fontana, DE, Bizzaro, N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Autoimmun Highlights 2017;8:9. https://doi.org/10.1007/s13317-017-0097-2. 4. Monogioudi, E, Martos, G, Hutu, DP, Schimmel, H, Meroni, PL, Sheldon, J, et al.. Standardization of autoimmune testing – is it feasible? Clin Chem Lab Med 2018;56:1734–42. https://doi.org/10.1515/cclm-2017-1077. 5. Bevilacqua, V, Chan, MK, Chen, Y, Armbruster, D, Schodin, B, Adeli, K. Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort. Clin Chem 2014;60:1532–42. https://doi.org/10.1373/clinchem.2014.229799.
|
|